Anzeige
Meldung des Tages: ALLZEITHOCH: EchoIQ bei 1$ AUD – der größte Trigger steht unmittelbar bevor

Cybin News

Aktie
WKN:  A40NJY ISIN:  CA23256X4075 US-Symbol:  HELP Branche:  Biotechnologie Land:  Kanada
4,615 €
-0,01 €
-0,22%
09:55:12 Uhr
Depot/Watchlist
Marktkapitalisierung *
141,45 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Cybin News

09.03.26 - PR Newswire
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire
05.03.26 - GlobeNewswire
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Statistically significant (p Durable effects sustained through at least 6 months In Phase 1 trial most participants were ready for discharge within 3 hours 1 ; Acute effects lasted ~90 ...
05.03.26 - PR Newswire
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
Anxiety Treatment Boom: GAD Therapies Poised for Multi-​Billion Dollar Expansion PR Newswire
27.02.26 - PR Newswire
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire
26.02.26 - PR Newswire
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire
24.02.26 - PR Newswire
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Next-​Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity PR Newswire
11.02.26 - GlobeNewswire
Helus Pharma ernennt Michael Cola zum Chief Executive Officer für die Leitung der nächsten Skalierungs- und Durchführungsphase
Er ist ehemaliger President des Spezialpharmazeutika-​Geschäftsbereichs von Shire PLC („Shire“) mit über 30 Jahren Erfahrung auf dem Gebiet von Neurowissenschaften, seltenen ...
10.02.26 - GlobeNewswire
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty ...
10.02.26 - PR Newswire
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market PR Newswire
23.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
18.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
13.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
08.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
03.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
28.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
24.09.25 - IRW-Press
Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen
- Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-​Programm (deuteriertes Dimethyltryptamin, DMT) des Unternehmens zur ...
23.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
18.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
13.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire
08.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN PR Newswire

Newssuche

Videos

newspaper
07.04.26 +0,66%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »